This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty
by Zacks Equity Research
Booster dose of J&J's (JNJ) COVID-19 vaccine elicits comparable neutralizing activity and higher T-cell responses in previously-vaccinated persons with Comirnaty.
Is Oshares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab
by Zacks Equity Research
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
by Kinjel Shah
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan
by Kinjel Shah
FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe
Amgen (AMGN) Kyprolis Gets FDA Nod for Use With Darzalex Faspro
by Zacks Equity Research
Amgen (AMGN) gets FDA nod for the label expansion of Kyprolis in combination with Darzalex Faspro and dexamethasone for treating patients with multiple myeloma at first or subsequent relapse.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $158.08, marking a +1.38% move from the previous day.
Moderna's (MRNA) Stock Falls on Omicron Variant Concerns
by Zacks Equity Research
Moderna (MRNA) shares decline following a two-day rise as the Omicron-variant creates uncertainty with limited data. The next couple of weeks may provide a clearer picture.
J&J (JNJ) to Explore Omicron Version of its COVID Vaccine
by Zacks Equity Research
J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant
Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe
Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids
by Kinjel Shah
FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.
J&J (JNJ) Gets First Full Approval for COVID Jab in Canada
by Zacks Equity Research
Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Oracle, PepsiCo and Verizon Communications
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Oracle, PepsiCo and Verizon Communications
Top Analyst Reports for Johnson & Johnson, Netflix & Oracle
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Netflix, Inc. (NFLX), and Oracle Corporation (ORCL).
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults
by Zacks Equity Research
The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.
Implied Volatility Surging for Johnson & Johnson (JNJ) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Johnson & Johnson (JNJ) stock based on the movements in the options market lately.
Johnson & Johnson (JNJ) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: JNJ to Spin Off Consumer Unit, PFE Eyes EUA for COVID Pill
by Kinjel Shah
J&J (JNJ) decides to split into two companies. Pfizer (PFE) seeks nod for emergency use of COVID antiviral pill. Glaxo's (GSK) and AbbVie's (ABBV) drugs get approvals in new indications.
Retail-Focused Week Ahead
by Daniel Laboe
I wouldn't be surprised if we continued to trade in choppy waters throughout this retail-focused week
J&J (JNJ) to Separate Consumer Unit Into New Company, Stock Up
by Zacks Equity Research
J&J (JNJ) is set to divide itself into two publicly traded companies. One will be its consumer products, while the other will comprise its pharmaceuticals and medical devices segments.
Company News for Nov 15, 2021
by Zacks Equity Research
Companies in The news Are: JNJ,CPNG,ROLL,BRLT
Should WisdomTree U.S. Total Dividend ETF (DTD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DTD